Everyday Health on MSN
There’s a New Drug for Motion Sickness — the First in 40 Years
The FDA approved the pill Nereus (tradipitant) as a new treatment for vomiting caused by motion sickness, with fewer side ...
Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...
Does motion sickness turn you into a green, spewing mess? For plenty of people, the answer is yes. Current remedies may or ...
Stocktwits on MSN
VNDA stock on track to open at three-year high – FDA clears first new motion sickness drug in decades
Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo.
Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.
MedPage Today on MSN
FDA greenlights first motion sickness drug in more than 40 years
The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...
The FDA decision was based on results from three late-stage clinical studies, including two Phase 3 trials conducted in ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback